(Reuters) — A study of Abbott Laboratories’ Trilipix showed female patients who took the drug along with a statin experienced more heart problems than those on a statin alone, U.S. health regulators said.
However, the clinical significance of the finding was unclear, the U.S. Food and Drug Administration said. About 30 percent of the patients were women. An FDA advisory committee will discuss the findings of the trial, named ACCORD Lipid, on May 19.
Abbott Labs shares closed down 48 cents to $51.32 on Monday.
